Abstract
The determinants and biomedical consequences of variation in leukocyte telomere length (LTL), a proposed marker of biological age, are only partially understood. Here we report the creation and initial characterization of LTL measurements in 474,074 participants in UK Biobank. We confirm that older age and male sex associate with shorter LTL, with women on average ∼7 years younger in “biological age” than men. Compared to white Europeans, LTL is longer in African, Chinese and other major ancestries. Older paternal age at birth is associated with longer individual LTL. Higher white cell count is associated with shorter LTL, but proportions of white cell subtypes have weaker associations. Age, ethnicity, sex and white cell count explain ∼5.5% of LTL variance. Using paired samples from 1351 participants taken ∼5 years apart, we show the regression-dilution ratio for LTL is ∼0.65. This novel resource provides major opportunities to investigate LTL and multiple biomedical phenotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under Application Number 6077 and was funded by the UK Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council and British Heart Foundation (BHF) through MRC grant MR/M012816/1. C.P.N is funded by the BHF (SP/16/4/32697). V.C., C.A.B., C.M., V.B., Q.W., R.B., C.P.N. and N.J.S. are supported by the National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Centre (BRC-1215-20010). Cambridge University investigators are supported by the BHF (RG/13/13/30194; RG/18/13/33946), Health Data Research UK, NIHR Cambridge BRC (BRC-1215-20014), NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024) and MRC (MR/L003120/1). J.N.D. holds a BHF Personal Professorship and NIHR Senior Investigator Award. A.M.W. and E.A. received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant number 116074.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank has ethical approval from the North West Centre for Research Ethics Committee (Application 11/NW/0382), which covers the UK. UK Biobank obtained informed consent from all participants. Full details can be found at https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics. The work in this manuscript was approved by UK Biobank (Application 6077).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available to researchers through application to UK Biobank
